OTC:NUMIF

Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003

Retrieved on: 
Wednesday, April 17, 2024
FDA, Safety, Food, TSX, Principal investigator, Research, Depression, DSM-IV codes, Patient, CCR, Health, Drug development, MDD, Pharmaceutical industry

With the Phase 2 trial data, the U.S. Food and Drug Administration ("FDA") granted CYB003 breakthrough therapy designation, potentially shortening the drug development timeline.

Key Points: 
  • With the Phase 2 trial data, the U.S. Food and Drug Administration ("FDA") granted CYB003 breakthrough therapy designation, potentially shortening the drug development timeline.
  • The Phase 3 trial for CYB003 is planned to commence enrollment mid-2024 and focus on its safety and efficacy.
  • "The Phase 2 results from the CYB003 trials were impressive and demonstrated the potential for treating a serious condition that affects over 20 million Americans," said Dr. Thielking.
  • To learn more about enrolling in the CYB003 Phase 3 Trial, please visit this link .

Numinus Wellness Provides Corporate Update

Retrieved on: 
Monday, April 15, 2024
Dragon (magazine), FDA, Dragon, Psychedelic drug, TSX, Corporate action, Attention, Toronto Stock Exchange, MDMA, Mental health, Patient, Health, PAT, Ketamine, Organization, Nursing

VANCOUVER, BC, April 15, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, provides an update following unauthorized disclosure in an online newspaper which has come to its attention.

Key Points: 
  • VANCOUVER, BC, April 15, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, provides an update following unauthorized disclosure in an online newspaper which has come to its attention.
  • Numinus affirms that any decision by management to complete the Canadian Reorganization will take into account the needs of Numinus patients and employees as well as maximizing benefits of Numinus' stakeholders.
  • Numinus will provide a further update when information is available.
  • To continue to support healthcare professionals and reinforce its commitment to advancing novel psychedelic-assisted therapies in Canada, Numinus is introducing a pilot membership program under its Numinus Network initiative.

Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results

Retrieved on: 
Saturday, April 13, 2024
FDA, Clinical trial, CFO, Learning, Private practice, TSX, Doctor of Philosophy, Research, Webcast, ATM, Interest, Retirement, MDMA, PDUFA, Patient, Methamphetamine, Accreditation, CCR, PAT, Bank statement, Drug development, Ketamine, Growth, Pharmaceutical industry

VANCOUVER, BC, April 12, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 29, 2024 ("Q2 2024").

Key Points: 
  • VANCOUVER, BC, April 12, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 29, 2024 ("Q2 2024").
  • Sequentially, gross margin declined 310 basis points in Q2 2024 to 33.0% from 36.1% in Q1 2024, reflecting the decrease in revenue compared to the previous quarter.
  • Wellness clinics generated revenue of $4.3 million during Q2 2024, a 9.5% decrease compared to $4.7 million during Q2 2023.
  • To participate in the live conference call, please use the following dial-in information:
    Please ask to participate in Numinus' Q2 2024 Results Call.

Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024

Retrieved on: 
Tuesday, April 9, 2024
Webcast, TSX, Interest

Interested parties are invited to participate in the Company's Q2 2024 results conference call and webcast, which will be held on the same day at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time.

Key Points: 
  • Interested parties are invited to participate in the Company's Q2 2024 results conference call and webcast, which will be held on the same day at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time.
  • During the call, Numinus executives will review the Company's performance and recent initiatives.
  • At this time, the operator will provide instructions for qualified equity analysts to submit questions.
  • A selection of questions will be answered by management on the call, and all emailed questions will be responded to by email.

Numinus Wellness Submits Clinical Trial Application

Retrieved on: 
Wednesday, March 20, 2024
Knowledge, Research, TSX, Clinical trial, Psychotherapy, MDMA, PTSD, Nursing

VANCOUVER, BC, March 20, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that it has submitted a Clinical Trial Application to Health Canada to examine the feasibility of a group model in MDMA-assisted psychotherapy enrolling trainee practitioners as participants.

Key Points: 
  • VANCOUVER, BC, March 20, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that it has submitted a Clinical Trial Application to Health Canada to examine the feasibility of a group model in MDMA-assisted psychotherapy enrolling trainee practitioners as participants.
  • If approved, the trial would allow Numinus to study MDMA-assisted psychotherapy with groups and better understand the optimum number of therapists required to deliver the programs safely.
  • The clinical trial is formally titled "Phase 1 Exploration of Feasibility and Optimal Therapist Numbers in Group Model MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and Practitioner Training."
  • Details on participating in the clinical trial will be posted on the Numinus website at https://numinus.com/en-ca/clinical-trials/ .

Numinus Wellness Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
Research, Mental health, Chair, Education, Software as a service, Audit, Risk management, CFO, TSX-V, Patient, Hospital, AGM, Controller, Worksafe, Date, TSX, Annual general meeting, Committee on Finance, Wellness, Interim management, Retirement, Interim, Pixelworks, CPA, Management

Mr. Garner has been a member of the Numinus Board since May 2020 and served on the Company's Audit and Compensation Committees.

Key Points: 
  • Mr. Garner has been a member of the Numinus Board since May 2020 and served on the Company's Audit and Compensation Committees.
  • "Ed has been a board member of Numinus since we first listed and has provided valuable counsel over that time," said Payton Nyquvest, Founder, Chair, and CEO of Numinus.
  • Donna Wilson brings to Numinus over two decades of executive management experience in the public and private sectors.
  • Donna Wong has extensive experience in corporate governance, risk management, and public company corporate finance, primarily in the healthcare and technology sectors.

Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder

Retrieved on: 
Friday, March 8, 2024
Anxiety, Research, MindMed, FDA, TSX, GAD, Clinical trial, Psychotherapy, Pharmaceutical industry

Based on initial clinical data from the Phase 2b trial and the significant unmet medical need in treating GAD, the U.S. Food & Drug Administration ("FDA") has designated MM120 for GAD as a breakthrough therapy.

Key Points: 
  • Based on initial clinical data from the Phase 2b trial and the significant unmet medical need in treating GAD, the U.S. Food & Drug Administration ("FDA") has designated MM120 for GAD as a breakthrough therapy.
  • Numinus' Cedar Clinical Research Draper Utah research clinic was among the highest enrolling sites for the study, with its clinic at Murray, Utah, also participating.
  • Dr. Reid Robison, Numinus' Chief Clinical Officer and Dr. Paul Thielking, Chief Science Officer, were Principal Investigators.
  • "We look forward to continuing to work with MindMed as it advances its important research into MM120.

Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024

Retrieved on: 
Tuesday, January 2, 2024
Interest, TSX, Webcast, Communications satellite

Interested parties are invited to participate in the Company's Q1 2024 results conference call and webcast occurring on the same day at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time.

Key Points: 
  • Interested parties are invited to participate in the Company's Q1 2024 results conference call and webcast occurring on the same day at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time.
  • During the call, Numinus executives will review the Company's performance and recent initiatives.
  • A replay of the conference call can also be accessed after 8:30 p.m. Eastern time / 5:30 p.m. Pacific time on January 15, 2024, at 1-800-770-2030 or 1-647-362-9199 (using passcode 3547386).
  • The replay will be available until January 29, 2024.

Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD

Retrieved on: 
Wednesday, December 13, 2023
NDA, Priority review, Research, OTCQB, Food, Breakthrough therapy, OTCQX, MDMA, Learning management system, Psychotherapy, Toronto Stock Exchange, MAPS, Anime International Company, FDA, OTC Markets Group, PTSD, DEA, TSX, News, Gisela Falke von Lilienstein, Nursing, Pharmaceutical industry

"This great news for the psychedelic-assisted therapy community and the millions of Americans struggling with PTSD," said Payton Nyquvest, Founder and CEO of Numinus.

Key Points: 
  • "This great news for the psychedelic-assisted therapy community and the millions of Americans struggling with PTSD," said Payton Nyquvest, Founder and CEO of Numinus.
  • With its established clinic network and qualified professionals, along with our training pathway, Numinus is ready to offer MDMA-assisted therapy pending regulatory approvals."
  • As noted in the MAPS release : "With Breakthrough Therapy designation given to MDMA in 2017, MAPS PBC has requested the FDA grant Priority Review of the NDA.
  • Anticipating the demand for MDMA-Assisted Therapy, Numinus has recently expanded its Practitioner Training Program to address the potential shortfall in trained therapists.

Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results

Retrieved on: 
Wednesday, November 29, 2023
Psilocybin, EBITDA, Health Canada, Research, CCR, Ageing, MDMA, Learning management system, Clinical trial, PAT, MAPS, FDA, Trial of the century, Partnership, Conditional sentence, Growth, TSX, Payment card, Health care, Nursing, Pharmaceutical industry, Beauty salon, Phoenix

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months and fiscal year ended August 31, 2023 ("Q4 2023").

Key Points: 
  • VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months and fiscal year ended August 31, 2023 ("Q4 2023").
  • For the fiscal year ending August 31, 2023, revenue increased by 256.9% over the previous fiscal year.
  • On an annual basis, the gross margin was 36.1% in fiscal year 2023, compared to 27.4% in fiscal year 2022.
  • Numinus Bioscience will remain a legal entity under Numinus Wellness Inc., ensuring the Company will retain all intellectual property, patents, and regulatory licenses.